We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Drove Glaukos Stock's 48% Rally Since the End of September?
Read MoreHide Full Article
Key Takeaways
GKOS shares rallied 48.2% since September-end, driven by record Q3 revenues and a sharp guidance increase.
Glaukos raised its 2026 sales outlook to $775-$785 million and projects $1 billion in revenues for 2027.
Strong Epioxa and iDose sales, positive clinical results and retinal pipeline expansion bolster GKOS' outlook.
Glaukos (GKOS - Free Report) shares have surged 48.2% since September-end, significantly outperforming the industry’s 7.6% growth over the same time frame. The S&P 500 Index has declined 3.8% during the period.
The sharp rally has been primarily supported by significantly stronger-than-expected third-quarter performance, which prompted a substantial increase in full-year sales guidance. Positive clinical developments for Epioxa and iDose TR, along with an expansion of the retinal pipeline, have further strengthened the company’s growth outlook.
The company is increasingly transitioning from a glaucoma-focused business into a broader ophthalmology platform spanning glaucoma, corneal disease, retinal disorders and other chronic eye conditions.
Image Source: Zacks Investment Research
Factors Benefiting GKOS
Third-Quarter Results Provide the Biggest Catalyst: Glaukos’ third-quarter results appear to have been the principal catalyst behind the stock’s recent advancement. The company reported record revenues of $211 million (up 58% year over year), which beat the Zacks Consensus Estimate by 25%. Adjusted earnings per share (EPS) of 47 cents beat estimates by a whopping 491.7%.
The company had incurred an adjusted loss of 16 cents per share in the year-ago period. The scale of the outperformance indicated that demand for the company’s recently launched therapies was translating into faster-than-anticipated commercial growth. After the strong quarterly results, the stock opened $30 above its Oct. 28 closing price and ended the session up 33.6%.
Adjusted gross margin increased nearly 400 basis points year over year to approximately 88%, while adjusted net income reached $28.5 million. Cash generation exceeded $50 million, reflecting improving operating leverage as the higher-growth products accounted for a larger share of sales.
Strong third-quarter results led management to raise its 2026 net sales guidance to $775-$785 million from $680-$700 million, increasing the midpoint by $90 million. It also introduced preliminary 2027 revenue guidance of $1 billion, indicating more than 25% growth. The substantially higher outlook reinforced expectations that Epioxa and iDose TR could sustain the company’s growth trajectory. This combination of a large earnings beat, stronger margins and an upward guidance revision likely drove a significant reassessment of Glaukos’ earnings potential.
Clinical Evidence May Accelerate iDose Adoption: The U.S. Glaucoma franchise also delivered strong growth, generating $118.6 million in third-quarter sales, up 47%, with iDose TR contributing approximately $76 million. In October, Glaukos announced positive Phase 4 results evaluating iDose TR alongside cataract surgery. The combination achieved an 11.1 mmHg reduction in intraocular pressure, compared with 7.4 mmHg for cataract surgery alone, demonstrating an incremental treatment effect of 3.6 mmHg. The results broaden the clinical evidence supporting iDose TR across treatment settings and could help reinforce adoption.
Epioxa Strengthens Commercial Growth Prospects: The third-quarter performance was supported by strong contributions from both major growth platforms. Epioxa generated approximately $53 million in sales, helping the Corneal Health franchise reach $59 million in revenues, gaining 154% year over year. Broader treatment access is supporting the launch. Treatment centers now serve areas home to roughly 90% of the U.S. population, while payer access pathways reach approximately 90% of people with commercial insurance and more than 80% of Medicaid enrollees. This progress suggests that Glaukos is building the distribution and reimbursement foundation required to expand the market for keratoconus treatment.
Clinical evidence added to this opportunity. Last month, Glaukos announced positive three-year extension results for Epioxa, showing sustained improvements in corneal shape and visual acuity following a single treatment, alongside a favorable long-term safety profile. The findings support the therapy’s potential for durable outcomes and could strengthen physician confidence as commercialization expands.
Retinal Pipeline Expansion Adds Long-Term Potential: Glaukos also took a strategic step toward broadening its presence in retinal diseases. Last month, it entered into an exclusive license agreement with RevOpsis Therapeutics for RO-104, a first-in-class tri-specific biologic targeting multiple pathways involved in retinal vascular diseases.
The agreement also provides rights to the RevMod platform to develop up to four additional biologic candidates. Although this opportunity is earlier-stage and does not materially change near-term revenue expectations, it expands Glaukos’ potential growth platforms beyond glaucoma and corneal health.
Glaukos is competing across several distinct ophthalmology markets, with Alcon (ALC - Free Report) and Sight Sciences (SGHT - Free Report) representing directly comparable competitive exposures. Alcon’s third-quarter results showed 5% overall growth. Although its cataract and implantable portfolio continued its strong performance through PanOptix Pro, the implantable business sales have declined 2% due to competitive pressures.
ALC’s contact lens and ocular-health franchises also provide scale and diversification. Sight Sciences delivered 25% revenue growth and is building its own interventional glaucoma and dry-eye platform. SGHT’s combined OMNI and SION revenues rose 6.7% year over year and TearCare revenues improved 44.4% sequentially. Aetna added about 25 million covered lives for OMNI and SION.
Although AbbVie’s (ABBV - Free Report) retinal portfolio is not a significant portion of its business, the company has a presence in Glaukos’ targeted markets — sustained-release implants, MIGS and wet AMD. AbbVie commercializes Durysta as a biodegradable sustained-release implant for open-angle glaucoma or ocular hypertension. ABBV markets the XEN Gel Stent as a MIGS device to lower intraocular pressure. The company is also developing a pipeline candidate for treating wet AMD.
Against Alcon, ABBV and Sight Sciences, GKOS stands out for its concentrated exposure to underpenetrated interventional eye-care markets and exceptionally rapid revenue growth. However, Alcon offers greater scale, while Sight Sciences is intensifying competition in MIGS.
Concerns for GKOS
Despite the stronger outlook, Glaukos faces execution and reimbursement risks. Epioxa remains in the early stages of launch. Payer approvals, referral development and site capacity must translate into repeatable treatment volumes. iDose TR faces potential local coverage determinations that could constrain Medicare access.
The RO-104 program and broader pipeline require substantial R&D investment, with uncertain clinical and regulatory outcomes. Rising SG&A and R&D spending may also moderate margin expansion as commercialization accelerates.
Conclusion
Glaukos’ rally reflects a strong earnings surprise, higher revenue guidance and stronger contributions from Epioxa and iDose TR. Positive clinical results and the expansion of its retinal pipeline add further support to its long-term growth prospects. Sustaining the momentum will depend on continued launch execution, broader patient access and the ability to convert its growing pipeline into commercial opportunities. With GKOS sporting a Zacks Rank #1 (Strong Buy), investors can add it to their portfolio and gain from its exceptional growth potential. Currently, the highest price target for GKOS reflects a 10.3% upside potential, compared to the closing price as of Nov. 18, 2026. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Image: Bigstock
What Drove Glaukos Stock's 48% Rally Since the End of September?
Key Takeaways
Glaukos (GKOS - Free Report) shares have surged 48.2% since September-end, significantly outperforming the industry’s 7.6% growth over the same time frame. The S&P 500 Index has declined 3.8% during the period.
The sharp rally has been primarily supported by significantly stronger-than-expected third-quarter performance, which prompted a substantial increase in full-year sales guidance. Positive clinical developments for Epioxa and iDose TR, along with an expansion of the retinal pipeline, have further strengthened the company’s growth outlook.
The company is increasingly transitioning from a glaucoma-focused business into a broader ophthalmology platform spanning glaucoma, corneal disease, retinal disorders and other chronic eye conditions.
Image Source: Zacks Investment Research
Factors Benefiting GKOS
Third-Quarter Results Provide the Biggest Catalyst: Glaukos’ third-quarter results appear to have been the principal catalyst behind the stock’s recent advancement. The company reported record revenues of $211 million (up 58% year over year), which beat the Zacks Consensus Estimate by 25%. Adjusted earnings per share (EPS) of 47 cents beat estimates by a whopping 491.7%.
The company had incurred an adjusted loss of 16 cents per share in the year-ago period. The scale of the outperformance indicated that demand for the company’s recently launched therapies was translating into faster-than-anticipated commercial growth. After the strong quarterly results, the stock opened $30 above its Oct. 28 closing price and ended the session up 33.6%.
Adjusted gross margin increased nearly 400 basis points year over year to approximately 88%, while adjusted net income reached $28.5 million. Cash generation exceeded $50 million, reflecting improving operating leverage as the higher-growth products accounted for a larger share of sales.
Strong third-quarter results led management to raise its 2026 net sales guidance to $775-$785 million from $680-$700 million, increasing the midpoint by $90 million. It also introduced preliminary 2027 revenue guidance of $1 billion, indicating more than 25% growth. The substantially higher outlook reinforced expectations that Epioxa and iDose TR could sustain the company’s growth trajectory. This combination of a large earnings beat, stronger margins and an upward guidance revision likely drove a significant reassessment of Glaukos’ earnings potential.
Clinical Evidence May Accelerate iDose Adoption: The U.S. Glaucoma franchise also delivered strong growth, generating $118.6 million in third-quarter sales, up 47%, with iDose TR contributing approximately $76 million. In October, Glaukos announced positive Phase 4 results evaluating iDose TR alongside cataract surgery. The combination achieved an 11.1 mmHg reduction in intraocular pressure, compared with 7.4 mmHg for cataract surgery alone, demonstrating an incremental treatment effect of 3.6 mmHg. The results broaden the clinical evidence supporting iDose TR across treatment settings and could help reinforce adoption.
Epioxa Strengthens Commercial Growth Prospects: The third-quarter performance was supported by strong contributions from both major growth platforms. Epioxa generated approximately $53 million in sales, helping the Corneal Health franchise reach $59 million in revenues, gaining 154% year over year. Broader treatment access is supporting the launch. Treatment centers now serve areas home to roughly 90% of the U.S. population, while payer access pathways reach approximately 90% of people with commercial insurance and more than 80% of Medicaid enrollees. This progress suggests that Glaukos is building the distribution and reimbursement foundation required to expand the market for keratoconus treatment.
Clinical evidence added to this opportunity. Last month, Glaukos announced positive three-year extension results for Epioxa, showing sustained improvements in corneal shape and visual acuity following a single treatment, alongside a favorable long-term safety profile. The findings support the therapy’s potential for durable outcomes and could strengthen physician confidence as commercialization expands.
Retinal Pipeline Expansion Adds Long-Term Potential: Glaukos also took a strategic step toward broadening its presence in retinal diseases. Last month, it entered into an exclusive license agreement with RevOpsis Therapeutics for RO-104, a first-in-class tri-specific biologic targeting multiple pathways involved in retinal vascular diseases.
The agreement also provides rights to the RevMod platform to develop up to four additional biologic candidates. Although this opportunity is earlier-stage and does not materially change near-term revenue expectations, it expands Glaukos’ potential growth platforms beyond glaucoma and corneal health.
Glaukos Corporation Price and Consensus
Glaukos Corporation price-consensus-chart | Glaukos Corporation Quote
Competition
Glaukos is competing across several distinct ophthalmology markets, with Alcon (ALC - Free Report) and Sight Sciences (SGHT - Free Report) representing directly comparable competitive exposures. Alcon’s third-quarter results showed 5% overall growth. Although its cataract and implantable portfolio continued its strong performance through PanOptix Pro, the implantable business sales have declined 2% due to competitive pressures.
ALC’s contact lens and ocular-health franchises also provide scale and diversification. Sight Sciences delivered 25% revenue growth and is building its own interventional glaucoma and dry-eye platform. SGHT’s combined OMNI and SION revenues rose 6.7% year over year and TearCare revenues improved 44.4% sequentially. Aetna added about 25 million covered lives for OMNI and SION.
Although AbbVie’s (ABBV - Free Report) retinal portfolio is not a significant portion of its business, the company has a presence in Glaukos’ targeted markets — sustained-release implants, MIGS and wet AMD. AbbVie commercializes Durysta as a biodegradable sustained-release implant for open-angle glaucoma or ocular hypertension. ABBV markets the XEN Gel Stent as a MIGS device to lower intraocular pressure. The company is also developing a pipeline candidate for treating wet AMD.
Against Alcon, ABBV and Sight Sciences, GKOS stands out for its concentrated exposure to underpenetrated interventional eye-care markets and exceptionally rapid revenue growth. However, Alcon offers greater scale, while Sight Sciences is intensifying competition in MIGS.
Concerns for GKOS
Despite the stronger outlook, Glaukos faces execution and reimbursement risks. Epioxa remains in the early stages of launch. Payer approvals, referral development and site capacity must translate into repeatable treatment volumes. iDose TR faces potential local coverage determinations that could constrain Medicare access.
The RO-104 program and broader pipeline require substantial R&D investment, with uncertain clinical and regulatory outcomes. Rising SG&A and R&D spending may also moderate margin expansion as commercialization accelerates.
Conclusion
Glaukos’ rally reflects a strong earnings surprise, higher revenue guidance and stronger contributions from Epioxa and iDose TR. Positive clinical results and the expansion of its retinal pipeline add further support to its long-term growth prospects. Sustaining the momentum will depend on continued launch execution, broader patient access and the ability to convert its growing pipeline into commercial opportunities. With GKOS sporting a Zacks Rank #1 (Strong Buy), investors can add it to their portfolio and gain from its exceptional growth potential. Currently, the highest price target for GKOS reflects a 10.3% upside potential, compared to the closing price as of Nov. 18, 2026. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.